The results of ROC curve indicated that all of the biomarkers have a favorable diagnostic effectiveness in discriminating DCM cases in subgroup 2, with an AUC of 0.979 (95% CI 0.932–1.000) in TCEAL4, AUC of 0.869 (95% CI 0.750–0.968) in ISG15, and AUC of 0.939 (95% CI 0.850–0.996) in RWDD1, AUC of 0.955 (95% CI 0.888–1.000) in ALG5, AUC of 0.874 (95% CI 0.701–1.000) in MRPL20, AUC of 0.966 (95% CI 0.917–0.998) in JTB and AUC of 0.953 (95% CI 0.888–0.996) in LITAF (Figures 9B–H). Here, ALG5 is linked to familial dilated cardiomyopathy.